Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BXF9

UPID:
TEKT3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9BXF9; B2RAS7; D3DTT0; Q8N5R5; Q96M48

BACKGROUND:
The protein Tektin-3 is integral to the formation and stability of ciliary and flagellar microtubules, contributing to the motility of cells and spermatozoa. Its role in microtubule inner protein (MIP) complexes and dynein-decorated doublet microtubules (DMTs) is vital for the normal functioning of cilia and flagella, structures essential for movement and fluid flow across cell surfaces.

THERAPEUTIC SIGNIFICANCE:
Given Tektin-3's crucial involvement in Spermatogenic failure 81, characterized by reduced sperm motility and structural defects, it emerges as a key target for therapeutic intervention. The exploration of Tektin-3's function offers a gateway to novel therapeutic strategies aimed at addressing male infertility issues, highlighting the protein's significance in reproductive medicine and beyond.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.